Across Africa and the Global South, effective healthcare delivery is frequently bottlenecked long before treatment begins. Advanced molecular diagnostics for critical conditions—including tuberculosis, HIV, hepatitis, and cervical cancer (HPV)—are overwhelmingly imported, expensive, and reliant on strict cold-chain infrastructure that rural and under-resourced health centers simply do not possess.
Egyptian DeepTech startup Reme-D is dismantling this dependence by building localized, temperature-resilient diagnostic infrastructure from North Africa.
The Cairo-based molecular diagnostics manufacturer has closed a $1.45 million pre-Series A funding round led by Anara Impact Capital, with participation from the Global Innovation Fund (GIF), Africa Health Ventures, and additional regional investors.
The transaction comes just months after Reme-D secured a $500,000 equity injection from the Global Innovation Fund in April, signaling strong institutional backing for homegrown African life sciences manufacturing.
Scaling Capacity: Moving to a 1,500 sqm Production Hub
The fresh injection of capital will fund a massive operational expansion aimed at increasing Reme-D’s manufacturing output tenfold.
To achieve this scale, the startup is transitioning its team—which has expanded from five to 50 employees—into a state-of-the-art 1,500 square meter manufacturing facility equipped with upgraded automated production systems.
┌───────────────────────────────────────────────────────────────────────────┐
│ REME-D SCALE & TRACTION MATRIX │
├───────────────────────────────┬───────────────────────────────────────────┤
│ Capital Raised (Pre-Series A) │ $1.45 Million │
│ Lead Investor │ Anara Impact Capital │
│ Manufacturing Footprint │ Expanding to 1,500 sqm facility (10x cap) │
│ Commercialized Portfolio │ 30 Diagnostic Products │
│ Total Tests Supplied │ 550,000+ Units │
│ Key Active Markets │ Egypt, Kenya, Sudan │
└───────────────────────────────┴───────────────────────────────────────────┘
Beyond scaling existing diagnostic panels, Reme-D is broadening its research and development pipeline to cover complex, high-demand areas including oncology (cancer testing) and genetic disorders.
Engineering Diagnostics for Harsh Operating Realities
Founded in 2023 by CEO Salma Tammam, Reme-D engineers nucleic acid extraction kits, amplification and detection reagents, and testing machinery designed specifically for challenging environments.
Traditional imported diagnostic kits often require continuous refrigeration and complex multi-step protocols. Reme-D’s proprietary formulations deliver:
-
Thermal Stability: Diagnostics remain stable in hot and humid climates without requiring uninterrupted cold-chain logistics.
-
Simplified Workflows: Shorter testing protocols allow lower-tier laboratories and field clinics to run advanced assays accurately.
-
Cost Advantage: Localized chemical synthesis and assembly significantly lower per-test costs compared to European or North American imports.
Reme-D’s technology has already gained international scientific recognition, backed by a pending US patent application covering its proprietary diagnostic chemistry. In a prominent real-world deployment, the startup recently equipped a solar-powered mobile laboratory commissioned by WHO Egypt to support vector-borne disease surveillance for the Egyptian Ministry of Health in off-grid regions.
Leadership and Investor Perspectives
“Success means that patients in Africa and the Global South are no longer blocked from life-altering disease diagnosis by cost or availability of an advanced molecular test in their area. This is our ultimate goal. We take particular pride in demonstrating what African science and African women can bring to the business world and global community, and we are grateful to be supported by a group of remarkable investors who share our desire for real-world positive impact.”
— Salma Tammam, Founder and CEO of Reme-D
“We were impressed by Salma and the Reme-D team’s ability to combine deep scientific expertise with a clear understanding of the realities of delivering diagnostics in underserved markets. Reme-D has already demonstrated that high-quality molecular diagnostics can be developed and manufactured locally, and we are excited to support the team as they scale their impact across MEA and beyond.”
— Mohamed Hussain, Principal at Anara Impact Capital
Ecosystem Takeaway: Bio-Manufacturing as Africa’s Next Frontier
Reme-D’s trajectory underlines a critical evolution in African HealthTech. While the first wave of regional digital health focused primarily on telemedicine software, pharmacy delivery apps, and health insurance aggregation, investors are increasingly realizing that long-term health sovereignty requires local hardware and biochemical manufacturing.
By establishing local manufacturing capability, securing international IP, and supplying over 550,000 commercial tests across North and East Africa in under three years, Reme-D is demonstrating that African deeptech ventures can compete on cost, quality, and clinical precision simultaneously.
